Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy.

Abstract

INTRODUCTION:

Tamoxifen has been used as adjuvant therapy for the treatment of breast cancer. Its use has been associated with the development of proliferative endometrial lesions such as polyps, hyperplasia, and carcinoma. Mesenchymal tumors including malignant mixed mullerian tumors, endometrial stromal sarcomas, adenosarcomas, and leiomyosarcomas have been more recently described with tamoxifen use.

CASE REPORT:

This report describes the first case of a pure uterine rhabdomyosarcoma in a patient receiving tamoxifen therapy.

DISCUSSION:

Although uterine rhabdomyosarcomas are rare tumors and may arise de novo, we discuss the possible role of tamoxifen in the development of these mesenchymal tumors.

• Authors: D H Okada, J B Rowland, L M Petrovic
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 75 Issue 3 Pg. 509-13 (Dec 1999) ISSN: 0090-8258 [Print] United States
• PMID: 10600318 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 1999 Academic Press.

Chemical References

• Antineoplastic Agents, Hormonal
• Tamoxifen

Topics

• Antineoplastic Agents, Hormonal (adverse effects)
• Breast Neoplasms (drug therapy)
• Female
• Humans
• Middle Aged
• Neoplasms, Second Primary (chemically induced, pathology)
• Rhabdomyosarcoma (chemically induced, pathology)
• Tamoxifen (adverse effects)
• Uterine Neoplasms (chemically induced, pathology)